Ann: Clarity strengthens Cu-64 network with new supply agreement, page-17

I think it's important to emphasise that whilst TLX, with a market cap of $5+ billion, has already got an established and highly profitable business in the very same radiopharmaceutical treatment of patients with prostate cancer.

This new "upstart" Clarity, with a market cap now approaching A$1 billion, has become a very serious threat to Telix through what appears to be a best-in-class imaging and therapy via its Cu64/Cu67 radioligand.

And Clarity's platform clearly has the potential to extend way beyond prostate cancer over time.

I'd certainly be worried if I was the CEO of TLX.